Diagnostic Performance of Whole-Body PET/MRI for Detecting Malignancies in Cancer Patients: A Meta-Analysis

Guohua Shen*, Shuang Hu*, Bin Liu, Anren Kuang*

Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, Sichuan, 610041, People’s Republic of China

☯ These authors contributed equally to this work.
* kuanganren@263.net

Abstract

Background

As an evolving imaging modality, PET/MRI is preliminarily applied in clinical practice. The aim of this study was to assess the diagnostic performance of PET/MRI for tumor staging in patients with various types of cancer.

Methods

Relevant articles about PET/MRI for cancer staging were systematically searched in PubMed, EMBASE, EBSCO and the Cochrane Library. Two researchers independently selected studies, extracted data and assessed the methodological quality using the QUA-DAS tool. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated per patient and per lesion. The summary receiver-operating characteristic (SROC) curves were also constructed, and the area under the curve (AUC) and Q* estimates were obtained.

Results

A total of 38 studies that involved 753 patients and 4234 lesions met the inclusion criteria. On a per-patient level, the pooled sensitivity and specificity with 95% confidence intervals (CIs) were 0.93 (0.90–0.95) and 0.92 (0.89–0.95), respectively. On a per-lesion level, the corresponding estimates were 0.90 (0.88–0.92) and 0.95 (0.94–0.96), respectively. The pooled PLR, NLR and DOR estimates were 6.67 (4.83–9.19), 0.12 (0.07–0.21) and 75.08 (42.10–133.91) per patient and 10.91 (6.79–17.54), 0.13 (0.08–0.19) and 102.53 (59.74–175.97) per lesion, respectively.

Conclusion

According to our results, PET/MRI has excellent diagnostic potential for the overall detection of malignancies in cancer patients. Large, multicenter and prospective studies with
standard scanning protocols are required to evaluate the diagnostic value of PET/MRI for individual cancer types.

---

**Introduction**

Cancer continues to be a major public health problem in the United States and many other parts of the world, and one in 4 deaths in the United States is due to cancer [1]. Knowing the exact tumor stage is essential for selecting the appropriate therapeutic strategies to provide the best available care and best prognosis for the patient.

Conventional imaging procedures, such as chest radiography, CT, and ultrasonography, are commonly used to detect malignant lesions and assess tumor staging. However, based only on the morphologic criteria, it is difficult to identify small lesions and to distinguish potential metastatic lesions from benign findings [2]. The integrated 18F-fluorodeoxyglucose positron emission tomography (FDG PET)/computed tomography (CT), which combines morphological and functional information, is helpful in tumor staging and is currently a major diagnostic tool in oncology [3,4]. Because it provides a higher level of accuracy in TNM staging than does either PET or CT alone, PET/CT is considered indispensable [5]. Magnetic resonance imaging (MRI), which has excellent soft-tissue contrast compared to CT, can improve tumor detection and delineation in body regions with difficult anatomy, such as the head and neck areas and gynecological regions. Integrated PET/MRI, which combines the excellent anatomical resolution and high soft-tissue contrast of MRI with the highly sensitive evaluation of metabolism and molecular processes of PET, has recently been applied in clinical practice as a new multimodality imaging [6,7]. Furthermore, functional MRI sequences, such as diffusion-weighted imaging (DWI) and other multiparametric sequences, can be added to the scanning protocol, which might enhance its diagnostic performance and predictive value [8,9]. Several published studies have shown the feasibility and efficacy of PET/MRI in tumor staging in various cancers [9-14]. Karsten et al have recently demonstrated the higher lesion conspicuity and diagnostic confidence of PET/MRI compared to PET/CT for the depiction and characterization of liver lesions [15]. PET/MRI is also a valuable technique for assessing primary tumor and nodal staging in patients with endometrial cancer as well as in patients with head and neck cancers [11,16]. However, these studies had relatively small sample sizes and limited power for an individual study.

In this study, we performed a meta-analysis to assess the diagnostic performance of PET/MRI in tumor staging systematically.

---

**Materials and Methods**

**Search strategy and study selection**

We searched for studies evaluating PET/MRI for tumor TNM staging in patients with various cancers, and relevant studies were identified with a comprehensive search of MEDLINE, EMBASE, EBCSO and the Cochrane Library from January 1, 2000 to October 1, 2015. The search strategy was based on the combination of (PET-MRI OR PET/MRI OR MRI-PET OR MRI/PET OR positron emission tomography/magnetic resonance imaging OR positron emission tomography-magnetic resonance imaging) AND (neoplasm OR cancer OR carcinoma) AND (staging OR diagnosis). References in the included studies were screened for additional studies.
Regarding the study selection, the inclusion criteria were as follows: (a) PET/MRI was used as a diagnostic tool for TNM staging in cancer patients; (b) there were sufficient data labeled as true-positive (TP), false-positive (FP), false-negative (FN) and true-negative (TN) results; (c) the data analysis was performed at either the patient level or the lesion level or both, and the minimal sample size was 10; (d) histopathologic results and/or clinical and imaging follow-up were used as the reference standard. We excluded reviews; meeting abstracts; letters; and case reports without absolute numbers of TP, FP, FN and TN estimates.

Data extraction and quality assessment

Two investigators independently extracted data from the included studies, and discrepancies were resolved by discussion. For each study, we collected information on author names; publication year; origin country; patient characteristics (number of eligible patients/lesions, gender, year); cancer type (head and neck, breast, lung, prostate, or others); study design (prospective or retrospective); scanning modality; and reference standard. We also recorded whether the interpretation of the PET/MRI was blinded to the reference standard. In addition, for each study, the numbers of TP, FP, FN and TN findings were recorded to perform accuracy analyses.

The methodology of the included studies was evaluated by the quality assessment tool for diagnostic accuracy studies (QUADAS) [17]. This tool consists of 14 items: patient spectrum (item 1), reporting of selection criteria (item 2), appropriate reference standard (item 3), absence of disease progression bias (item 4), absence of partial verification bias (item 5), absence of differential verification bias (item 6), absence of incorporation bias (item 7), description of test execution details (item 8), description of reference execution details (item 9), absence of test review bias (item 10), absence of diagnostic review bias (item 11), absence of clinical review bias (item 12), reporting of uninterpretable/intermediate results (item 13), and withdrawal (item 14). The majority of items are related to bias (items 3, 4, 5, 6, 7, 10, 11, 12 and 14), with only two items relating to variability (items 1 and 2) and three to reporting (items 8, 9 and 13) [18]. For each item, a score of “1” was recorded for “yes” and “0” for “no” or “unknown”. A score of 12 was the cut-off value between high quality and low quality. In addition, in our analysis histopathologic results and/or clinical and imaging follow-up results were used as the “reference standard”, and the examination of PET/MRI was regarded as the “index test”.

Statistical analysis

Based on the extracted data and bivariate regression models, both per patient and per lesion, we calculated the pooled sensitivity and specificity, which were weighted average estimates using the sample size as the weight for each study. Then, by using the pooled sensitivities and specificities, we also calculated diagnostic odds ratios (DORs), positive likelihood ratios (PLRs) and negative likelihood ratios (NLRs) for PET/MRI. All the pooled data were presented with 95% confidence intervals (CIs). In addition, the summary receiver operating characteristic (SROC) curves were constructed and the area under the curve (AUC) and Q^2 index were obtained.

An inconsistency index (I^2) test was performed to assess the degree of heterogeneity between studies, and herein I^2 describes the percentage of variability in point estimates that is due to heterogeneity rather than sampling error [19]. If the I^2 value was greater than 50%, meaning that a distinct heterogeneity was observed, the random-effect model was applied; otherwise, the fixed-effect model was used. We investigated the effect of heterogeneity on the diagnostic value of PET/MRI by subgroup analyses based on the study design, quality score,
scanning modality and reference standard. We also performed a sensitivity analysis and meta-regression analysis and tested the publication bias and threshold-effect.

All statistical computations were conducted with Stata version 12.0 and Meta-Disc version 1.4. *P* values less than 0.05 were considered to be statistically significant.

**Results**

**Eligible studies**

The initial electronic search yielded 565 articles, and after reviewing the title and abstract, 421 were excluded because of irrelevance. The full text of the remaining 144 articles was screened, and 106 studies were excluded for the following reasons: the studies did not provide any diagnostic information beyond therapeutic or predictive value (*n* = 24); the sample was too small (*n* = 8); there were insufficient data to obtain absolute numbers of TP, FP, FN or TN results (*n* = 68); or the reference standard was not histopathologic findings or a combination of histopathology and clinical follow-up (*n* = 6). Eventually, 38 articles [9–11,13,16,20–52] that included 753 patients and 4234 lesions were included in this meta-analysis. The flowchart of study selection is shown in Fig 1. Of the 38 articles, 17 were retrospective. The combination of histopathologic results and clinical and/or imaging follow-up was regarded as the reference standard in 23 articles. The detailed characteristics of the included studies are shown in Table 1.

**Quality assessment**

The results of the QUADAS are shown in Fig 2. Overall, 27 studies (for per-patient and/or per-lesion) fulfilled 12 or more of the 14 items in this meta-analysis, and these were regarded as the
| Study       | Year  | Origin | Design | Mean age | Gender (M/F) | Cancer type                                                                 | Blind | Imaging modality | Reference standard | Quality score | Analysis | No. of p/l |
|------------|-------|--------|--------|----------|--------------|-----------------------------------------------------------------------------|-------|------------------|-------------------|--------------|----------|-----------|
| Beiderwellen | 2015  | Germany | P      | 54±13 (25–72) | 0/19         | Cervical cancer, ovarian cancer                                             | B     | Integrated PET/MRI | HP+CFU            | 11           | Lesion   | 78        |
| Beiderwellen | 2015  | Germany | P      | 57±13 (27–74) | 12/20        | Malignant melanoma, breast cancer, colorectal cancer and others             | ND    | Integrated PET/MRI | HP+CFU            | 9            | Lesion   | 113       |
| Brendle     | 2015  | Germany | R      | 45(10–62)     | 9/6          | Colon cancer, sigmoid cancer, and rectal cancer                             | B     | Integrated PET/MRI | HP+CFU            | 10           | Lesion   | 180       |
| Paspulati   | 2015  | USA     | P      | 59         | 9/3          | Colorectal cancer                                                           | B     | Sequential PET/MRI | HP+CFU            | 12           | Patient  | 12        |
| Grueneisen  | 2015  | Germany | R      | 57±13 (27–74) | 0/24         | Ovarian cancer, cervical cancer and endometrial cancer                      | B     | Integrated PET/MRI | HP+CFU            | 10           | Lesion   | 104       |
| Nensa       | 2015  | Germany | P      | 57.5(20–83)  | 7/13         | metastases, direct infiltration via pulmonary vein, local relapse of primary sarcoma after surgery, Burkitt lymphoma, scar/patch tissue after surgery of primary sarcoma, myxoma, fibroelastoma, COMA, and thombus | ND    | Integrated PET/MR  | HP+CFU            | 11           | Patient  | 20        |
| Grueneisen  | 2015  | Germany | P      | 48±12 (28–73) | 0/27         | Primary cervical cancer                                                     | B     | Integrated PET/MRI | HP+CFU            | 12           | Patient  | 27        |
| Schaarschmidt | 2015  | Germany | R      | 56.5±7.7    | 23/2         | Head and neck squamous cell carcinoma                                       | B     | Integrated PET/MRI | HP+CFU            | 13           | Lesion   | 397       |
| Queiroz     | 2015  | Switzerland | P    | 60(37–81)   | 0/26         | Gynaecological malignancies                                                | ND    | trimodality PET/CT-MRI | HP+CFU            | 10           | Patient  | 26        |
| Grueneisen  | 2015  | Germany | P      | 56±12 (29–84) | 0/49         | Primary breast cancer                                                       | B     | Integrated PET/MRI | HP+CFU            | 12           | Lesion   | 83        |
| Gatidis     | 2015  | Germany | P      | 4.8(1–6)    | 6/3          | Primitive neuroectodermal tumor, posttransplant lymphoproliferative disorder, Rhabdomyosarcoma, Neuroblastoma, Coccygeal teratoma, Neurofibromatosis | ND    | Integrated PET/MRI | HP+CFU/IFU        | 12           | Patient  | 67        |
| Heusch      | 2015  | Germany | R      | 59(21–85)   | ND           | NSCLC, breast carcinoma, cancer of unknown primary site, head and neck tumor, melanoma of the uvea, genitourinary tumor, tumor of the gastrointestinal tract, malignant melanoma, pleural mesothelioma, liver tumor. | Blind | Integrated PET/MRI | HP+CFU/IFU        | 12           | Patient  | 26        |
| Taneja      | 2014  | India   | R      | 50.12 (34–75) | 0/36         | Breast cancer                                                               | ND    | Integrated PET/MRI | HP+CFU/IFU        | 10           | Patient  | 26        |
| Reiner      | 2014  | Switzerland | P    | 61(32–79)   | 33/22        | Liver metastasis (colorectal carcinoma, pancreatic carcinoma, gastrointestinal stromal tumour, cholangiocellular carcinoma, gastroesophageal carcinoma) | Blind | Trimodality PET/CT/MRI | HP+CFU            | 12           | Patient/ Lesion | 57/120   |
| Queiroz     | 2014  | Switzerland | P    | 63(24–90)   | 68/19        | Head and neck cancer                                                        | ND    | Trimodality PET/CT/MRI | HP+CFU            | 10           | Lesion   | 117       |
| Queiroz     | 2014  | Switzerland | P    | 63.8(26–86) | 53/17        | Head and neck cancer                                                        | ND    | Trimodality PET/CT/MRI | HP+CFU            | 11           | Lesion   | 188       |
| Platzek     | 2014  | Germany  | R      | 63(43–82)   | 30/8         | Head and neck cancer                                                        | Blind | Ingenuity TF PET/MR  | HP+CFU            | 12           | Lesion   | 391       |
| Platzek     | 2014  | Germany  | R      | 45(16–74)   | 16/11        | Hodgkin disease, diffuse large B-cell lymphoma, follicular lymphoma, anaplastic large-cell lymphoma, Burkitt lymphoma, cutaneous T-cell lymphoma | Blind | Ingenuity TF PET/MR  | HP+CFU            | 12           | Lesion   | 702       |
| Loeffelbein | 2014  | Germany  | R      | 57(27–72)   | 21/12        | Head and neck cancer                                                        | Blind | Software-fused PET +MRI | HP+CFU            | 12           | Patient  | 31        |

(Continued)
Table 1. (Continued)

| Study       | Year | Origin | Design | Mean age | Gender (M/F) | Cancer type                                | Blind       | Imaging modality           | Reference standard | Quality score | Analysis | No. of p/l |
|-------------|------|--------|--------|----------|--------------|--------------------------------------------|------------|---------------------------|-------------------|--------------|----------|-----------|
| Kubiessa    | 2014 | Germany| P      | 60(42–78)| 13/4         | Head and neck cancer                       | Blind      | Integrated PET/MRI         | HP+CFU            | 12           | Lesion   | 78        |
| Kitajima    | 2014 | Japan  | R      | 61.3(38–83)| 0/30        | Uterine cervical cancer, ovarian cancer, endometrial cancer | Blind      | Software-fused PET + MRI  | HP+CFU            | 12           | Patient  | 30        |
| Kitajima    | 2014 | Japan  | R      | 57.8(27–88)| 0/30        | Uterine cervical cancer                     | Blind      | Software-fused PET + MRI  | HP+CFU            | 12           | Patient  | 30        |
| Heusch      | 2014 | Germany| P      | 65(46–86) | 11/7        | Head and neck squamous cell carcinoma       | Blind      | Software-fused PET + MRI  | HP                | 12           | Lesion   | 288       |
| Heusch      | 2014 | Germany| P      | 65.1     | 12/10       | NSCLC                                       | Blind      | Integrated PET/MRI         | HP                | 12           | Patient  | 22        |
| Grueneisen  | 2014 | Germany| P      | 52.8(26–73)| 0/48       | Cervical cancer, vulvar cancer, vaginal cancer, endometrial cancer, ovarian cancer | Blind      | Integrated PET/MRI         | HP+CFU            | 12           | Lesion   | 122       |
| Bitencourt  | 2014 | Brazil | P      | 47.8(29–77)| 0/31       | Breast cancer                               | ND         | Software-fused PET + MRI  | HP                | 12           | Lesion   | 38        |
| Vargas      | 2013 | USA    | R      | 56(28–81) | 0/31        | Carcinoma of the cervix, endometrium or vaginal/vulva | Blind      | Software-fused PET + MRI  | HP                | 14           | Patient  | 31        |
| Nagamachi   | 2013 | Japan  | R      | 67.1(34–85)| 64/55       | Pancreatic tumor                            | Blind      | Software-fused PET + MRI  | HP                | 12           | Patient  | 119       |
| Kohan       | 2013 | USA    | P      | 66±8     | 2/9         | Lung cancer                                 | Blind      | Ingenuity PET/MRI          | HP+CFU/IFU        | 12           | Patient  | 44        |
| Kitajima    | 2013 | Japan  | R      | 62.4(30–88)| 0/30       | Endometrial cancer                          | Blind      | Software-based PET + MRI  | HP+CFU/IFU        | 12           | Patient  | 30        |
| Kanda       | 2013 | Japan  | R      | 66.9(37–91)| 24/6       | Squamous cell carcinoma of the oral cavity or hypopharynx | Blind      | Software-based PET + MRI  | HP                | 13           | Patient/ Lesion | 30/244  |
| Garibotto   | 2013 | France | P      | 51(6–89) | 6/9         | Neurodegenerative disease, epilepsy, high-grade tumor | ND         | Ingenuity TF PET/MRI      | HP+CFU            | 10           | Patient  | 15        |
| Pfluger     | 2012 | Germany| R      | 11       | 77/55       | Paediatric oncology                         | ND         | Software-fused PET + MRI  | HP+IFU           | 10           | Lesion   | 813       |
| Kam         | 2010 | Australia| R    | 60(46–75) | 15/8       | Rectal cancer                               | ND         | Software-fused PET + MRI  | HP                | 12           | Patient  | 23        |
| Donati      | 2010 | Switzerland| R    | 60.2(35–82)| 23/14      | Hepatic metastases                          | Blind      | Software-fused PET + MRI  | HP                | 13           | Patient/ Lesion | 37/85  |
| Estrada     | 2008 | Mexico | P      | 43       | 20/10      | Primary cerebral tumor                      | ND         | Software-fused PET + MRI  | HP+CFU            | 10           | Patient  | 30        |
| Huang       | 2011 | Taiwan | P      | 54(36–79) | 16/1       | Buccal squamous cell carcinoma              | Blind      | Software-fused PET + MRI  | HP                | 13           | Lesion   | 64        |

(Continued)
| Study     | Year | Origin | Design | Mean age | Gender (M/F) | Cancer type                  | Blind | Imaging modality          | Reference standard | Quality score | Analysis | No. of p/l |
|----------|------|--------|--------|----------|--------------|-----------------------------|-------|---------------------------|-------------------|--------------|----------|-----------|
| Nakamoto | 2009 | Japan  | R      | 62(27–81)| 50/15        | Head and neck cancer        | ND    | Software-fused PET+MRI    | HP+CFU            | 9            | Patient | 46        |

No: number; ND: unknown or no document; HP: histopathologic results; CFU/IFU: clinical/imaging follow-up; NSCLC: non-small cell lung cancer; P: prospective; R: retrospective; CCMA: caseous calcification of mitral annulus; NSCLC: non-small cell lung cancer; p/l: patient/lesion

doi:10.1371/journal.pone.0154497.t001
studies with high quality. The common weaknesses were centered on whether the time interval between the reference standard and the index test was acceptable (item 4) and whether the reference standard was the same regardless of the index test results (item 6). In addition, 9 studies did not indicate whether the reference standard and index test were masked to one another (item 10 and item 11).

### Diagnostic accuracy of PET/MRI

Per patient, the pooled sensitivity, specificity and DOR for PET/MRI were 0.93 (95% CI, 0.90–0.95), 0.92 (95% CI, 0.89–0.95) and 75.08 (95% CI, 42.10–133.91), respectively. The pooled PLR and NLR estimates were 6.67 (95% CI, 4.83–9.19) and 0.12 (95% CI, 0.07–0.21), respectively. The per-patient sensitivity analysis showed that no individual study contributed to the pooled values whereas, this analysis on a per-lesion level revealed that three studies had significant influence on the overall estimates [29,36,48]. After excluding these three studies, the summarized sensitivity, specificity and DOR per lesion were 0.90 (95% CI, 0.88–0.92), 0.95 (95% CI, 0.94–0.96) and 102.53 (95% CI, 59.74–175.97), respectively. A likelihood ratio syntheses yielded an overall PLR of 10.91 (95% CI, 6.79–17.54) and NLR of 0.13 (95% CI, 0.08–0.19). The results are shown in Table 2.

The SROC curves and the Q’ index on both a per-patient basis and a per-lesion basis are presented in Fig 3.

### Heterogeneity analysis

The I² estimates were 64.8% for pooled sensitivity on a per-patient basis, 80.0% for pooled sensitivity on a per-lesion basis, and 80.0% for pooled specificity on a per-lesion basis, indicating significant heterogeneity among included studies. The heterogeneity of pooled specificity was
low only on a per patient basis ($I^2 = 30.4\%$). The results of the heterogeneity analysis are shown in Table 2.

To explore the source of heterogeneity, Spearman’s correlation test was used to evaluate the threshold effect, and its coefficient was determined to be 0.527 ($P = 0.014$) per patient and 0.358 ($P = 0.16$) per lesion, indicating an absence of the threshold effect. With regard to publication bias, the results of the Deeks funnel plots were not significant ($P = 0.185$ for per patient, $P = 0.748$ for per lesion), suggesting no major publication bias (Fig 4).

The results of the subgroup analysis are also shown in Table 2. The study design, quality score, reference standard and scanning modality did not significantly influence the reported sensitivities and specificities of PET/MRI on a per-lesion level ($P > 0.05$). On a per-patient level, only scanning modality had a significant influence on the sensitivity of PET/MRI. In other words, the subgroup of integrated PET/MRI had a higher sensitivity than that of software-fused PET/MRI ($P < 0.05$). The results of a single-factor meta-regression analysis showed that no factor significantly influenced the diagnostic accuracy of PET/MRI.

With regard to cancer type, due to limited information and small sample sizes, we only pooled the diagnostic estimates for head and neck cancer on a per-lesion level.

Table 2. The diagnostic accuracy of PET/MRI for detection of malignant lesions.

| Study          | No. of studies | Sensitivity | $I^2$ | Specificity | $I^2$ | AUC    | $Q^*$  |
|----------------|----------------|-------------|------|-------------|------|--------|-------|
| **Per-patient**|                |             |      |             |      |        |       |
| All            | 21             | 0.93(0.90–0.95) | 64.8% | 0.92(0.89–0.95) | 30.4% | 0.9545 | 0.8967 |
| **Study Design**|                |             |      |             |      |        |       |
| Prospective    | 9              | 0.94(0.88–0.97) | 44.7% | 0.90(0.84–0.95) | 42.8% | 0.9548 | 0.8971 |
| Retrospective  | 12             | 0.92(0.89–0.95) | 73.9% | 0.93(0.89–0.96) | 20.1% | 0.9647 | 0.9115 |
| **QUADAS**     |                |             |      |             |      |        |       |
| High quality   | 15             | 0.91(0.87–0.94) | 65.9% | 0.93(0.89–0.96) | 34.9% | 0.9601 | 0.9047 |
| Low quality    | 6              | 0.98(0.94–1.00) | 17.7% | 0.89(0.75–0.96) | 21.7% | 0.9556 | 0.8982 |
| **Reference standard** | |             |      |             |      |        |       |
| HP             | 8              | 0.93(0.88–0.96) | 72.6% | 0.93(0.87–0.97) | 9.3%  | 0.9704 | 0.9205 |
| HP+CFU         | 13             | 0.93(0.88–0.96) | 61.7% | 0.92(0.88–0.95) | 42.6% | 0.9511 | 0.8920 |
| **Modality**   |                |             |      |             |      |        |       |
| Integrated PET/MRI | 10          | 0.90(0.83–0.94) | 54.1% | 0.92(0.87–0.96) | 33.1% | 0.9513 | 0.8922 |
| Software-Fused PET+MRI | 11    | 0.94(0.91–0.97) | 70.6% | 0.93(0.88–0.96) | 34.3% | 0.9691 | 0.9183 |
| **Per-lesion** |                |             |      |             |      |        |       |
| All            | 17             | 0.90(0.88–0.92) | 80.0% | 0.95(0.94–0.96) | 80.0% | 0.9641 | 0.9105 |
| **Study Design**|                |             |      |             |      |        |       |
| Prospective    | 13             | 0.91(0.89–0.93) | 82.5% | 0.93(0.92–0.95) | 78.1% | 0.9611 | 0.9062 |
| Retrospective  | 4              | 0.85(0.80–0.90) | 40.3% | 0.97(0.96–0.99) | 71.4% | 0.9365 | 0.8731 |
| **QUADAS**     |                |             |      |             |      |        |       |
| High quality   | 12             | 0.89(0.86–0.92) | 83.0% | 0.96(0.94–0.97) | 77.7% | 0.9676 | 0.9161 |
| Low quality    | 5              | 0.91(0.87–0.94) | 73.1% | 0.91(0.87–0.94) | 81.9% | 0.9496 | 0.8899 |
| **Reference standard** | |             |      |             |      |        |       |
| HP             | 9              | 0.86(0.82–0.90) | 80.2% | 0.96(0.94–0.97) | 82.7% | 0.9635 | 0.9097 |
| HP+CFU         | 8              | 0.92(0.89–0.94) | 78.9% | 0.92(0.89–0.94) | 73.1% | 0.9683 | 0.9170 |
| **Modality**   |                |             |      |             |      |        |       |
| Integrated PET/MRI | 12          | 0.92(0.89–0.94) | 71.3% | 0.95(0.93–0.96) | 83.2% | 0.9652 | 0.9122 |
| Software-Fused PET+MRI | 5    | 0.83(0.77–0.88) | 87.5% | 0.95(0.93–0.97) | 72.3% | 0.9610 | 0.9059 |

AUC: area under the curve, HP: histopathologic results, CFU: clinical follow-up; in parentheses: the 95% confidence interval.

doi:10.1371/journal.pone.0154497.t002
corresponding estimates of 8 studies [9,16,20,34,39,46,49] were 0.83 (95% CI, 0.79–0.87) for sensitivity, 0.96 (95% CI, 0.94–0.97) for specificity and 81.20 (95% CI, 42.27–155.97) for DOR.

**Discussion**

When making decisions regarding cancer therapy, it is necessary to have precise knowledge of the local tumor stage as well as to detect potential metastasis to regional lymph nodes and distant organs. In this study, we performed a meta-analysis to evaluate the diagnostic accuracy of integrated PET/MRI or software-fused PET/MRI for tumor staging in patients with various cancers, and the results showed that PET/MRI had excellent diagnostic performance for the overall detection of malignancies.
Likelihood ratios enable characterizing clinical diagnostic tests to establish diagnoses for individual patients [53]. The discriminating ability is better, with a higher PLR and lower NLR. In general, a PLR greater than 10.0 would be required to confirm the presence of disease, and an NLR less than 0.1 would be required to eliminate the possibility. Per patient, the PLR was not high enough to diagnose malignancies, but it was high enough per lesion. Because the NLRs were not low enough on a per-patient or a per-lesion level, a negative PET/MRI finding alone might not rule out a malignancy. The DOR is the ratio of PLR to NLR and ranges from 0 to infinity. The greater the DOR, the better the performance of the diagnostic test, and the DOR in this meta-analysis showed that PET/MRI performed well.

A comparative study of PET/MRI, PET/CT, MRI, and CT imaging for assessing surrounding tissue invasion of advanced buccal squamous cell carcinoma reported that PET/MRI had highest sensitivity and specificity among the 4 modalities (90.0%/90.9%, 80.0%/84.1%, 80.0%/79.5%, and 55.0%/81.8%, respectively) [37]. Similarly, in head and neck cancer, PET-MRI fusion has higher sensitivity/specificity for tumor staging (89%/100%), compared with that of MRI (79%/66%) and that of PET (82%/100%) [49]. In addition, Kitajima found that for T-status staging of cervical cancer, PET/MRI proved significantly more accurate than PET/CT (83.3% vs. 53.3%).[10] Summarizing the available evidence, in several specific regions such as head, neck and pelvic regions, PET/MRI might be more accurate for primary tumor staging compared with conventional imaging methods or PET/CT. One potential explanation might be the high soft-tissue contrast of MRI in these regions [10,37,38]. MRI could provide an accurate assessment of the local tumor extent to determine the extent of tumor resection and the adjuvant therapy. However, due to scar tissue, loss of symmetry and side shift, MRI alone may not help differentiate between non-neoplastic and neoplastic changes in operated regions [54]. Currently, PET might provide additional metabolic information for the differential diagnosis, although it might have some false positive findings [55]. Therefore, the detection of invasion of the adjacent anatomical structures is a potential advantage of PET/MRI for primary tumor staging. However, in some other common tumors, such as NSCLC and liver metastatic lesions, PET/MRI does not provide higher accuracy for detecting malignancies [33,40]. With regard to tumor N staging, several previous studies have shown that PET/MRI and PET/CT were of equal diagnostic accuracy. Kohan reported that PET/MRI using three-segment model attenuation correction showed substantial inter-observer agreement and a similar performance to PET/CT in N staging of lung cancer. In head and neck cancers, PET/MRI did not significantly improve the accuracy for detecting cervical lymph node metastases compared to MRI or PET [35]. In addition, PET/MRI is feasible for lymphoma staging and has a high sensitivity and specificity for nodal involvement in lymphoma (93.8% for sensitivity and 99.4% for specificity) [36]. Because the detection of lymph node metastases is predominantly based on the functional information of PET, which is highly sensitive, the differences between PET/MRI and PET/CT were not significant. In a few studies, additional functional MRI sequences, such as DWI, were shown to potentially help detect metastatic lymph nodes showing no enlargement [56]. However, several other studies have shown no additional diagnostic value of DWI in PET/MRI for the detection of metastases [39,41,57]. For M staging, only one study was analyzed, and the result suggested that no significant differences were observed between PET/MRI and PET/CT [24]. By increasing the sample size and testing efficiency and reducing random error, our meta-analysis revealed that PET/MRI has excellent diagnostic accuracy for tumor staging on both a per-patient and a per-lesion level. However, the heterogeneity between studies was significant, and the sources should be investigated.

To determine whether the threshold effect was an impact factor, it was evaluated by Spearman’s correlation. The estimate of 0.358 (P = 0.16) per lesion revealed that no significant threshold effect existed, while the estimate of 0.527 (P = 0.014) per patient indicated a notable
threshold effect. The reason for the notable threshold effect lies in the combination of high sensitivity and low specificity or vice versa. For example, Nakamoto et al showed the highest sensitivity (1.00) and the lowest specificity (0.67) [13]. By contrast, Kam showed the lowest sensitivity (0.44) and the highest specificity (1.00) [50]. The feature of significant differences was mainly caused by different diagnostic cut-off values in individual studies. Additionally, the results of the Deeks funnel plot asymmetry test provided no evidence of notable publication bias ($P = 0.185$ per patient, $P = 0.748$ per lesion). Based on the putative factors of study design, quality score, reference standard and scanning modality, we performed the subgroup analysis, and the results showed that only scanning modality significantly contributed to the heterogeneity on a per-lesion level. The integrated PET/MRI system can achieve better and more consistent image registration accuracy than can the software-based fusion of PET and MRI, further yielding better diagnostic performance [58].

We performed an additional assessment for other sources of heterogeneity. The diagnostic performance for staging might depend on primary tumor type, target organ of potential metastases and scanning protocols. For example, while PET/MRI may be superior for hepatic staging or head and neck cancers, its application can be limited for detecting small pulmonary metastases [59]. However, we could not perform any further analysis for each cancer type due to small sample sizes and limited information. Regarding the scanning protocol, for which there is no consensus, most studies used FDG PET/unenhanced T1-weighted MRI images, but some studies [10, 11, 38] used the contrast enhanced imaging or organ-specific imaging protocol. Moreover, some studies investigated the value of software-fused PET/MRI while others focused on the value of integrated PET/MRI; the latter had more precise anatomic fusion and location. Finally, the sequence of subsequent PET/MRI acquisitions might influence the diagnostic results [16]. The delayed PET acquired during FDG PET/MRI would show more lesions because of tracer accumulation in malignant lesions [60]. All these differences may have biased the pooled estimates of PET/MRI for tumor staging.

There are some limitations in this study. First, the exclusion of conference abstracts and letters may have led to reporting bias. Although the Deeks test revealed an absence of publication bias, it could still exist because studies with optimistic results might be published more easily. Second, we did not perform subgroup analyses for each cancer type due to limited information and small sample sizes. Third, there was no standard scanning modality and protocol, which might affect the pooled accuracy of PET/MRI and be a main source of between-studies heterogeneity. The reference standards used were not the same and included histopathological findings alone and in combination with clinical/imaging follow-up. Fourth, approximately 55% of the included studies were retrospective, which might be a potential limitation because of the risk that investigators might have known the results of other imaging modalities or clinical examinations before evaluating the PET/MRI images. Fifth, we did not compare the value of PET/MRI with that of PET/CT due to limited information, which might lead to an incomplete knowledge of PET/MRI in clinical practice.

**Conclusions**

Current evidence shows that PET/MRI has excellent diagnostic performance for overall tumor staging. Large, multicenter and prospective studies with standard scanning protocols are required to evaluate the diagnostic value of PET/MRI for individual cancer types. Additionally, a comparison of PET/MRI with other modalities especially PET/CT is urgently needed.

**Supporting Information**

S1 PRISMA Checklist. PRISMA 2009 Checklist.

(DOC)
Author Contributions

Conceived and designed the experiments: GHS SH. Performed the experiments: BL GHS. Analyzed the data: GHS SH ARK. Contributed reagents/materials/analysis tools: GHS SH ARK. Wrote the paper: GHS SH ARK. Provided critical input into the design and drafting of the manuscript: GHS BL SH ARK.

References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64: 9–29.
2. Xu G, Zhao L, He Z. Performance of whole-body PET/CT for the detection of distant malignancies in various cancers: a systematic review and meta-analysis. J Nucl Med. 2012; 53: 1847–1854. doi: 10.2967/jnumed.112.105409 PMID: 23073605
3. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging. 2009; 36: 15–29.
4. Schiepers C, Dahlbom M. Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging. Eur Radiol. 2011; 21: 548–554. doi: 10.1007/s00330-010-2033-y PMID: 21174096
5. Antoch G, Vogt FM, Freundenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003; 290: 3199–3206. PMID: 14693872
6. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012; 53: 928–938. doi: 10.2967/jnumed.112.105338 PMID: 22582048
7. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012; 53: 1244–1252. doi: 10.2967/jnumed.112.109306 PMID: 22782313
8. Chawla S, Kim S, Dougherty L, Wang S, Loevner LA, Quon H, et al. Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck. AJR Am J Roentgenol. 2013; 200: 35–43. doi: 10.2214/AJR.12.9432 PMID: 23255739
9. Queiroz M, Hüllner M, Kuhn F, Huber G, Meerwein C, Kollias S, et al. Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation. Eur J Nucl Med Mol Imaging. 2014; 41: 2212–2221. doi: 10.1007/s00259-014-2867-7 PMID: 25091219
10. Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Deguchi M, et al. Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced 18F-FDG PET/CT and pelvic MRI. Clin Imaging. 2014; 38: 464–469. doi: 10.1016/j.clinimag.2014.02.006 PMID: 24642250
11. Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Takahashi S, et al. Value of fusion of PET and MRI for staging of endometrial cancer: Comparison with 18F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI. Eur J Radiol. 2013; 82: 1672–1676. doi: 10.1016/j.ejrad.2013.05.005 PMID: 23727380
12. Maurer T, Beer A, Souvatzoglou M, Holzapfel K, Kubler H, Gschwend J, et al. Staging of intermediate and high-risk prostate cancer using whole body 68Gallium-labelled ligand of prostate-specific membrane antigen PET/MRI. J Urol. 2014; 191(suppl): e471.
13. Nakamoto Y, Tamai K, Saga T, Higashi T, Hara T, Suga T, et al. Clinical value of image fusion from MR and PET in patients with head and neck cancer. Mol Imaging Biol. 2009; 11: 46–53. doi: 10.1007/s11307-008-0168-x PMID: 18769975
14. Pinker K, Bickel H, Magometschnigg H, Bruck B, Bogner W, Gruber S, et al. Molecular imaging of breast tumours with PET-MRI-proof of concept. Eur J Cancer. 2012; 48(suppl 1): S63.
15. Beiderwellen K, Gomez B, Buchbender C, Hartung V, Poeppel TD, Nensa F, et al. Depiction and characterization of liver lesions in whole body [18F]-FDG PET/MRI. Eur J Radiol. 2013; 82: e669–e675. doi: 10.1016/j.ejrad.2013.05.005 PMID: 24011443
16. Kubiessa K, Purz S, Gawlitza M, Kühn A, Fuchs J, Steinhofer K, et al. Initial clinical results of simultaneous F-FDG PET/MRI in comparison to F-FDG PET/CT in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2014; 41: 639–646. doi: 10.1007/s00259-013-2633-2 PMID: 24292111
17. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006; 6: 9. PMID: 16519814
18. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003; 3: 25. PMID: 14606960

19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539–1558. PMID: 12111919

20. Schaarschmidt BM, Heusch P, Buchbender C, Ruhlmann M, Bergmann C, Ruhlmann V, et al. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI. Eur J Nucl Med Mol Imaging. 2016; 43: 92–102. doi: 10.1007/s00259-015-3145-z PMID: 26243264

21. Queiroz MA, Kubik-Huch RA, Hauser N, Freiwald-Chilla B, von Schulthess G, Froehlich JM, et al. PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. Eur Radiol. 2015; 25: 2222–2300. doi: 10.1007/s00330-015-3657-8 PMID: 26017734

22. Pasupati RM, Partovi S, Herrmann KA, Krishnamurthi S, Delaney CP, Nguyen NC. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study. Abdom Imaging. 2015; 40: 1415–1425. doi: 10.1007/s00261-015-4074-0 PMID: 26112492

23. Nensa F, Tezgah E, Poeppel TD, Jensen CJ, Schelhorn J, Kohler J, et al. Integrated 18F-FDG PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial experience and comparison. Eur J Nucl Med Mol Imaging. 2015; 42: 2222–2300. doi: 10.1007/s00259-015-3131-5 PMID: 26199113

24. Grueneisen J, Schaarschmidt BM, Heubner M, Suntharalingam S, Milk I, Kinner S, et al. Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. Eur J Radiol. 2015; 84: 2097–2102. doi: 10.1016/j.ejrad.2015.08.010 PMID: 26321491

25. Beiderwellen K, Grueneisen J, Schaarschmidt BM, Heubner M, Aktas B, Kinner S, Forsting M, et al. Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging. 2015; 42: 1814–1824. doi: 10.1007/s00259-015-3137-z PMID: 26191131

26. Gatidis S, Schmidt H, Gucke B, Beznukov I, Seitz G, Ebinger M, et al. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Invest Radiol. 2016; 51: 7–14. doi: 10.1097/RLI.0000000000000197 PMID: 26115367

27. Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, et al. FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015; 42: 56–65. doi: 10.1007/s00259-014-2902-8 PMID: 25223420

28. Reiner C, Stolzmann P, Husmann L, Burger I, Hüllner M, Schaefer N, et al. Protocol requirements and diagnostic value of PET/IMR imaging for liver metastasis detection. Eur J Nucl Med Mol Imaging. 2014; 41: 649–658. doi: 10.1007/s00259-013-2654-x PMID: 24346415

29. Queiroz MA, Hullner M, Kuhn F, Huber G, Meerwein C, Kollias S, et al. PET/MRI and PET/CT in follow-up of head and neck cancer patients. Eur J Nucl Med Mol Imaging. 2014; 41: 1066–1075. doi: 10.1007/s00259-014-2707-9 PMID: 24577950
35. Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Kitzler HH, Maus J, et al. FDG PET/MR for lymph node staging in head and neck cancer. Eur J Radiol. 2014; 83: 1163–1168. doi: 10.1016/j.ejrad.2014.03.023 PMID: 24746792

36. Platzek I, Beuthien-Baumann B, Ordemann R, Maus J, Schramm G, Kitzler HH, et al. FDG PET/MR for the Assessment of Lymph Node Involvement in Lymphoma. Initial Results and Role of Diffusion-Weighted MR. Acad Radiol. 2014; 21: 1314–1319. doi: 10.1016/j.acra.2014.05.019 PMID: 25086953

37. Loeffelbein DJ, Souvatzioglou M, Wankert V, Dinges J, Ritschl LM, Müller C, et al. Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer. BMC cancer. 2014; 14: 846. doi: 10.1186/1471-2407-14-846 PMID: 24129541

38. Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Makihara N, et al. Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor: comparison with 18F-FDG contrast-enhanced PET/CT and pelvic MRI. Ann Nucl Med. 2014; 28: 25–32. doi: 10.1007/s12149-013-0777-6 PMID: 24129541

39. Heusch P, Sproll C, Buchbender C, Rieser E, Terjung J, Antke C, et al. Diagnostic accuracy of ultrasound, F-FDG-PET/CT, and fused F-FDG-PET-MR images with DWI for the detection of cervical lymph node metastases of HNSCC. Clin Oral Investig. 2014; 18: 969–978. doi: 10.1007/s00784-013-1050-z PMID: 23892450

40. Heusch P, Buchbender C, Köhler J, Nensa F, Gauer T, Gomez B, et al. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014; 55: 379–378. doi: 10.2967/jnumed.13.139825 PMID: 24504054

41. Grueneisen J, Schaarschmidt BM, Beiderwellen K, Schulze-Hagen A, Heubner M, Kinner S, et al. Diagnostic Value of Diffusion-Weighted Imaging in Simultaneous 18F-FDG PET/MR Imaging for Whole-Body Staging of Women with Pelvic Malignancies. J Nucl Med. 2014; 55: 1930–1935. doi: 10.2967/jnumed.14.146886 PMID: 25453042

42. Bitencourt AG, Lima EN, Chojniak R, Marques EF, Souza JA, Andrade WP, et al. Multiparametric Evaluation of Breast Lesions Using PET-MRI: Initial Results and Future Perspectives. Medicine. 2014; 93: e115. doi: 10.1097/MD.0000000000000115 PMID: 25396329

43. Vargas HA, Burger IA, Donati OF, Andikyan V, Lakhman Y, Goldman DA, et al. Magnetic resonance imaging/postion emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration. Int J Gynecol Cancer. 2013; 23: 1512–1519. doi: 10.1097/IGC.0b013e318217566f PMID: 23765244

44. Nagamachi S, Nishii R, Wakamatsu H, Mizutani Y, Kiyohara S, Fujita S, et al. The usefulness of (18)F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with (18)F-FDG PET/CT. Ann Nucl Med. 2013; 27: 554–563. doi: 10.1007/s12149-013-0719-3 PMID: 23580090

45. Kohan AA, Kolthammer JA, Vercher-Conejero JL, Rubbert C, Partovi S, Jones R, et al. Staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience. Eur Radiol. 2013; 23: 3161–3169. doi: 10.1007/s00330-013-2914-y PMID: 23765261

46. Kanda T, Kitajima K, Suenaga Y, Konishi J, Sasaki R, Morimoto K, et al. Value of retrospective image fusion of 18F-FDG PET and MRI for preoperative staging of head and neck cancer: Comparison with PET/CT and contrast-enhanced neck MRI. Eur J Radiol. 2013; 82: 1168–1174. doi: 10.1016/j.ejrad.2013.06.025 PMID: 23891295

47. Garibotto V, Heinzer S, Vulliémoz S, Guignard R, Wissmeyer M, Seeck M, et al. Clinical applications of hybrid PET/MRI in neuroimaging. Clin Nucl Med. 2013; 38: e113–e118. doi: 10.1097/RLU.0b013e3182638ea6 PMID: 23242058

48. Pflugger T, Melzer H, Mueller W, Coppenrath E, Bartenstein P, Albert M, et al. Diagnostic value of combined F-FDG-PET/MRI for staging and restaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2012; 39: 1745–1755. doi: 10.1007/s00259-012-2228-3 PMID: 22962713

49. Huang S-H, Chien C-Y, Lin W-C, Fang F-M, Wang P-W, Lui C-C, et al. A comparative study of fused FDG PET/MRI, PET/CT, MRI, and CT imaging for assessing surrounding tissue invasion of advanced buccal squamous cell carcinoma. Clin Nucl Med. 2011; 36: 518–525. doi: 10.1097/RLU.0b013e1821756e66 PMID: 21637051

50. Kam MH, Wong DC, Sui S, Stevenson ARL, Lai J, Phillips GE. Comparison of magnetic resonance imaging-fluorodeoxyglucose positron emission tomography with pathological staging in rectal cancer. Br J Surg. 2010; 97: 266–268. doi: 10.1002/bjs.6886 PMID: 20035542

51. Donati OF, Hany TF, Reiner CS, van Schultess GK, Marincek B, Seifert B, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010; 51: 692–699. doi: 10.2967/jnumed.109.068510 PMID: 20395324

52. Estrada G, González-Maya L, Celis-López MA, Gavito J, Lárraga-Gutiérrez JM, Salgado P, et al. Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI,
visual and quantitative analysis, and three dimensional stereotactic surface projections. First experience in Mexico. Rev Esp Med Nucl. 2008; 27: 329–339. PMID: 18817662
53. Sonis J. How to use and interpret interval likelihood ratios. Farm Med. 1999; 31: 432–437.
54. Offiah C, Hall E. Post-treatment imaging appearances in head and neck cancer patients. Clin Radiol. 2011; 66: 13–24. doi: 10.1016/j.crad.2010.09.004 PMID: 21147294
55. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake – the role of PET/CT. Eur Radiol. 2006; 16: 1054–1065. PMID: 16365730
56. Vandecaveye V, De Keyzer F, Vander Poorten V, Verbeken E, Nuyts S, et al. Head and Neck Squamous Cell Carcinoma: Value of Diffusion-weighted MR Imaging for Nodal Staging 1. Radiology. 2009; 251: 134–146. doi: 10.1148/radiol.2511080128 PMID: 19251938
57. Buchbender C, Hartung-Knemeyer V, Beiderwellen K, Heusch P, Kühl H, Lauenstein TC, et al. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: Does it benefit lesion detection? Eur J Radiol. 2013; 82: 877–882. doi: 10.1016/j.ejrad.2013.01.019 PMID: 23428414
58. Judenhofer MS, Cherry SR. Applications for preclinical PET/MRI. Semin Nucl Med. 2013; 43: 19–29. doi: 10.1053/j.semnuclmed.2012.08.004 PMID: 23178086
59. Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. Semin Nucl Med. 2015; 45: 268–281. doi: 10.1053/j.semnuclmed.2015.03.004 PMID: 26050655
60. Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, et al. Usefulness of Integrated PET/MRI in Head and Neck Cancer: A Preliminary Study. Nucl Med Mol Imaging. 2014; 48: 98–105. doi: 10.1007/s13139-013-0252-2 PMID: 24900149